[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012011431A8 - Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato - Google Patents

Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato

Info

Publication number
BR112012011431A8
BR112012011431A8 BR112012011431A BR112012011431A BR112012011431A8 BR 112012011431 A8 BR112012011431 A8 BR 112012011431A8 BR 112012011431 A BR112012011431 A BR 112012011431A BR 112012011431 A BR112012011431 A BR 112012011431A BR 112012011431 A8 BR112012011431 A8 BR 112012011431A8
Authority
BR
Brazil
Prior art keywords
sphingosine
compounds
phosphate receptor
receptor
methods
Prior art date
Application number
BR112012011431A
Other languages
English (en)
Other versions
BR112012011431A2 (pt
Inventor
F Boehm Marcus
Martinborough Esther
Brahmachary Enugurthi
Moorjani Manisha
Tamiya Junko
Huang Liming
Richard Yeager Adam
Original Assignee
Receptos Llc
Receptos Inc
Celgene Int Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptos Llc, Receptos Inc, Celgene Int Ii Sarl filed Critical Receptos Llc
Publication of BR112012011431A2 publication Critical patent/BR112012011431A2/pt
Publication of BR112012011431A8 publication Critical patent/BR112012011431A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

COMPOSTOS HETEROCÍCLICOS SELETIVOS MODULADORES DE RECEPTOR DE ESFINGOSINA 1 FOSFATO, SEUS USO E MÉTODO DE SÍNTESE, COMPOSIÇÃO FARMACÊUTICA, BEM COMO MÉTODO DE ATIVAÇÃO OU AGONISMO DO REFERIDO RECEPTOR A presente invenção refere-se a compostos que modulam seletivamente o receptor de esfingosina 1 fosfato, incluindo os compostos que modulam o subtipo 1 do receptor S1P. Proporcionam-se os métodos de síntese quiral desses compostos. Os usos, os métodos de tratamento ou prevenção, e os métodos de preparação das composições inventivas, incluindo os compostos inventivos, são proporcionados em relação ao tratamento ou prevenção de doenças, más condições, e distúrbios aos quais a modulação do receptor de esfingosina 1 fosfato é medicamente indicada.
BR112012011431A 2009-11-13 2010-11-15 Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato BR112012011431A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26129509P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056759 WO2011060391A1 (en) 2009-11-13 2010-11-15 Selective heterocyclic sphingosine 1 phosphate receptor modulators

Publications (2)

Publication Number Publication Date
BR112012011431A2 BR112012011431A2 (pt) 2015-10-06
BR112012011431A8 true BR112012011431A8 (pt) 2017-12-26

Family

ID=43992105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011431A BR112012011431A8 (pt) 2009-11-13 2010-11-15 Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato

Country Status (18)

Country Link
US (3) US8507538B2 (pt)
EP (1) EP2498609B1 (pt)
JP (1) JP5922027B2 (pt)
KR (1) KR101771755B1 (pt)
CN (2) CN105130922A (pt)
AU (1) AU2010319982B2 (pt)
BR (1) BR112012011431A8 (pt)
CA (1) CA2780641C (pt)
DK (1) DK2498609T3 (pt)
EA (1) EA025672B1 (pt)
ES (1) ES2675799T3 (pt)
HK (1) HK1213873A1 (pt)
IL (1) IL219692A (pt)
MX (1) MX2012005559A (pt)
MY (1) MY169497A (pt)
NZ (1) NZ599914A (pt)
PT (1) PT2498609T (pt)
WO (1) WO2011060391A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5650233B2 (ja) * 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
US8357706B2 (en) * 2009-11-13 2013-01-22 Receptos, Inc. Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
CN104395285B (zh) * 2012-06-21 2016-04-13 卫材R&D管理有限公司 二氢茚磺酰胺衍生物
JP6294359B2 (ja) 2013-02-20 2018-03-14 エルジー・ケム・リミテッド スフィンゴシン−１−リン酸受容体アゴニスト、その製造方法及びそれらを活性成分として含有する医薬組成物
CN106187945A (zh) * 2016-07-22 2016-12-07 辽宁师范大学 一种有机合成中间体的合成方法
WO2018028557A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 三环类化合物及其应用
BR112020017835A2 (pt) 2018-03-20 2020-12-29 Eisai R&D Management Co., Ltd. Agente de tratamento de epilepsia
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
KR20220043047A (ko) * 2020-09-28 2022-04-05 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제의 용도
TW202402285A (zh) * 2020-09-28 2024-01-16 南韓商Ｌｇ化學股份有限公司 神經鞘胺醇－１－磷酸受體促效劑的用途
KR20220142379A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 습식과립법에 의한 스핑고신-1-인산 수용체 효능제를 포함하는 경구용 고형 제제의 제조 방법
WO2022220593A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물
JP2024514184A (ja) * 2021-04-14 2024-03-28 エルジー・ケム・リミテッド 粒度が制御されたスフィンゴシン－１－リン酸受容体アゴニストを含む医薬組成物
CN117120038A (zh) * 2021-04-14 2023-11-24 株式会社Lg化学 包含鞘氨醇-1-磷酸受体激动剂的固体制剂的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) * 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
NZ505599A (en) 1998-01-23 2003-06-30 Sankyo Co Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists
DE60335827D1 (de) * 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006245349A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) * 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
EP2007749A2 (en) * 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
JP5837417B2 (ja) * 2008-05-14 2015-12-24 ザ スクリプス リサーチ インスティテュート スフィンゴシンリン酸受容体の新規なモジュレーター

Also Published As

Publication number Publication date
AU2010319982A1 (en) 2012-05-31
DK2498609T3 (en) 2018-06-18
US8507538B2 (en) 2013-08-13
EP2498609B1 (en) 2018-04-18
WO2011060391A1 (en) 2011-05-19
EP2498609A4 (en) 2013-05-22
IL219692A0 (en) 2012-07-31
US20140039183A1 (en) 2014-02-06
BR112012011431A2 (pt) 2015-10-06
JP5922027B2 (ja) 2016-05-24
KR101771755B1 (ko) 2017-08-25
MX2012005559A (es) 2012-08-23
IL219692A (en) 2017-06-29
CN102753022B (zh) 2016-04-20
EA201290329A1 (ru) 2012-12-28
US20110183953A1 (en) 2011-07-28
PT2498609T (pt) 2018-07-06
ES2675799T3 (es) 2018-07-12
CN105130922A (zh) 2015-12-09
MY169497A (en) 2019-04-15
US20150252037A1 (en) 2015-09-10
EP2498609A1 (en) 2012-09-19
CA2780641A1 (en) 2011-05-19
EA025672B1 (ru) 2017-01-30
CA2780641C (en) 2019-03-05
HK1213873A1 (zh) 2016-07-15
JP2013510884A (ja) 2013-03-28
KR20120094491A (ko) 2012-08-24
CN102753022A (zh) 2012-10-24
AU2010319982B2 (en) 2016-02-04
NZ599914A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
BR112012011431A8 (pt) Moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato
BR112012011430A8 (pt) Compostos moduladores de receptor de esfingosina 1 fosfato e composições farmacêuticas
BR112012011427B8 (pt) moduladores seletivos de receptor de esfingosina 1 fosfato, seu uso, e composição
BR112012008823B8 (pt) compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112015015468B8 (pt) Composto, e, composição farmacêutica
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BRPI0919876A8 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
IL199972A (en) Tricyclic compounds and their use as modulators of glucocorticoid receptor
WO2012158550A3 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
BRPI0916622A2 (pt) derivados de piperazina usados como moduladores de canal de cálcio cav2,2
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BR112012009121A2 (pt) Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
GT201400242A (es) "nuevos compuestos de pirazol"
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
BRPI0808353B8 (pt) usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados
BR112012014235A2 (pt) tiazóis bicíclicos como moduladores alostéricos de receptores mglur5
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: RECEPTOS LLC (US)

B25G Requested change of headquarter approved

Owner name: RECEPTOS LLC (US)

B25A Requested transfer of rights approved

Owner name: CELGENE INTERNATIONAL II SARL (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: RECEPTOS LLC (US)

B25G Requested change of headquarter approved

Owner name: RECEPTOS LLC (US)